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1. Introduction
  Psoriasis is an auto immune disease that affects the 
skin. It occurs when the immune system mistakes the 
skin cells as a pathogen, and sends out faulty signals 
that speed up the growth cycle of skin cells. It is a 
chronic inflammatory and proliferative skin disorder 
involving the interplay of both environmental and 
genetic factors[1]. Psoriasis is not contagious. However, 
psoriasis has been linked to an increased risk of stroke. 
There are five types of psoriasis: plaque, guttate, 
inverse, pustular and erythrodermic. 
  The most common form, plaque psoriasis, is 
commonly seen as red and white hues of scaly patches 
appearing on the top first layer of the epidermis 
(skin). Some patients, though, have no dermatological 
signs or symptoms. In plaque psoriasis, skin rapidly 
accumulates at these sites, which gives it a silvery-
white appearance. 
   Plaques frequently occur on the skin of the elbows 
and knees, but can affect any area, including the 
scalp, palms of hands and soles of feet and genitals. In 
contrast to eczema, psoriasis is more likely to be found 
on the outer side of the joint[2].
2. Materials and methods
2.1. Materials
  
  Psoralen and Barbaloin were purchased from Yucca 
Enterprises, Mumbai. All other materials, solvents and 
reagents were of analytical grade. 
2.2. Identification of drug
2.2.1. Thin layer chromatographic method (TLC)
  TLC was performed by dissolving drug in methanol. 
Mobile phase was prepared. Drug solution was spotted 
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the pre-coated TLC plate and was placed in saturation 
chamber. After the development of the TLC plate, the 
plate was air dried and the spot was detected by spray 
reagent. The Rf (Retardation factor) value was calculated 
using the following formula[3]:
  R f = Distance travelled by solute front/Distance 
travelled by solvent front
2.2.2. Investigation of physicochemical compatibility of 
drug and polymer
  The physicochemical compatibility between Psoralen 
and formulation excipients used in the gel formulations 
was studied by using Fourier transform infrared 
spectroscopy (FTIR-AT-001, Bruker). Infrared (IR) 
spectra were recorded using an FTIR in the wavelength 
region between 4 000 and 400 cm-1. The spectra obtained 
for Psoralen and physical mixtures of Psoralen with 
formulation excipients were compared[4].
2.2.3. Scanning electron microscopy (SEM)
  SEM is a type of electron microscopy that images a 
sample by scanning it with a beam of electrons in a 
raster scan pattern. The electrons interact with the 
atoms that make up the sample producing signals 
that contain information about the sample’s surface, 
topography, composition and other properties such as 
electrical conductivity[2].
2.3. Preparation of formulations
  The composition of different gel formulations is shown 
in Table 1.
  Accurately weighed amount of polymer was added to 
the required quantity of the distilled water which was 
kept under stirring at 37 °C. Gelling agent was added 
slowly to the polymer dispersion. After attaining the gel 
consistency required amount of drug (0.5 g) dissolved in 
methanol (5 mL) was added. Antioxidant, humectants, 
preservative were added with continuous stirring until a 
homogenous gel was formed.
2.4. Analytical method
  All samples were analyzed for Psoralen content 
spectrophotometrically at a wavelength of 246 nm.
2.5. Evaluation of prepared psoralen gel
2.5.1. pH
  To determined pH, 1 g of each gel formulation were 
transferred into 10 mL beaker and measured by using 
the digital pH meter[4].
2.5.2. Viscosity measurements
  A Brookfield Rotational Digital Viscometer DV II 
RVTDV- II was used to measure the viscosity (in cps) 
of gel formulations. The spindle was rotated at 10 r/min 
and the samples were allowed to settle over 30 min at 
the temperature [(25±1) °C] before the measurements 
were taken[5].
2.5.3. Spreadability and consistency
  The spreadability of gel formulation was determined 
by measuring 1 g of gel between horizontal plates for 
1 min. Consistency reflects the capacity of the gel to get 
ejected in uniform and desired quantity when the tube 
is squeezed.
2.5.4. Homogeneity
  All developed gels were tested for homogeneity by 
visual inspection after the gels have been set in the 
Table 1
Composition of psoralen gel formulation (%, w/w).
Materials
  Formulation code
 F1  F2  F3  F4  F5  F6  F7  F8
Psoralen (g)        0.05        0.05        0.05        0.05        0.05        0.05        0.05        0.05
Sodium alginate (g)        0.75        0.75  -  -  -  -  -  -
Egg albumin (g)  -  -        0.75        0.75  -  -  -  -
Bovine albumin (g)  -  -  -  -        0.75        0.75  -  -
Pectin (g)  -  -  -  -  -  -        4        5
Xanthan gum (g)        0.50  -        0.75  -        0.75  -  -  -
Guar gum (g)  -        0.50  -        0.75  -        1.75  -  -
Menthol (g)        0.25        0.25        0.25        0.25        0.25        0.25        0.25        0.25
α-Tocopherol (g)        0.50        0.50        0.50        0.50        0.50        0.50        0.50        0.50
Barbaloin (g)        0.005        0.005        0.005        0.005        0.005        0.005        0.005        0.005
Glycerine (mL)  -  -  -  -  -  -        5  -
Eugenol (mL)        0.01        0.01        0.01        0.01        0.01        0.01        0.01        0.01
Methanol (mL)      10      10      10      10      10      10      10      10
Distilled water q.s. to make (mL)      50      50      50      50      50      50      50      50
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container. They were tested for their appearance and 
presence of any aggregates.
2.5.5. Drug content
  All samples were analyzed for Psoralen content prior 
to diffusion studies. Drug content of gel formulations 
(1 g) was determined by dissolving an accurately weighed 
quantity of formulation in about 50 mL of pH 6.8 
phosphate buffer. 
  The resulting solutions were filtered and subjected to 
spectrophotometric analysis at λmax 246 nm. If necessary 
further dilutions were made using the same buffer 
solution. Drug content was thus calculated. 
2.5.6. In-vitro diffusion study
  The diffusion studies were performed by applying 
1 g of the gel uniformly to the dialysis membrane. The 
membrane was mounted between the compartments of 
Franz diffusion cell. Reservoir compartment was filled 
with 15 mL of 6.8 pH phosphate buffer. 
   The study was carried out at (37±2) °C and was carried 
out for 24 h. The sample (1 mL) was withdrawn from 
reservoir compartment in successive intervals. Each 
time reservoir compartment was replenished with 1 mL 
of 6.8 pH phosphate buffer solution to maintain sink 
condition[2].
2.5.7. Release kinetic study
  Data obtained from in-vitro release studies of the 
Psoralen from various gel formulations were fitted to 
various kinetic equations such as zero order, First order, 
Higuchi model and Korsmeyer-Peppas model.
2.5.8. Stability studies
  Stability testing of drug product being as a part of 
drug discovery and ends with the commercial product, 
to assess the drug and formulation stability, stability 
studies were done. 
  The stability study was carried out for the most 
satisfactory formulation. The most satisfactory 
formulation was kept at 0 °C, (27±2) °C and (40±2) °C. At 
the end of 1 month, the samples were analyzed for the 
drug content and in-vitro diffusion study[2,5].
2.5.9. Biological evaluation
  The anti-psoriatic activity was performed on the 
mouse-tail. The mouse-tail model is based on the 
induction of orthokeratosis in those parts of the adult 
mouse-tail, which have a normally parakeratotic 
differentiation. The Perry scientific mouse tail method 
is used and it is accepted as a screening method for 
measuring anti-psoriatic activity of drugs. 
  The basis of this method is that topical treatment 
of a mouse-tail with anti-psoriatic drugs enhances 
orthokeratotic cell differentiation in the epidermal 
scales. This characteristic was utilized for direct 
measurement of drug efficacy in animal model[6]. Drug 
activity is defined by the increase in percentage of 
orthokeratotic regions. Drug activity is calculated by 
using the formula:
  DA = (Mean orthokeratosis of treated group–Mean 
orthokeratosis of control group)/(100–Mean orthokeratosis 
of controlled group)×100.
 
3. Results
3.1. Preformulation studies
3.1.1. TLC
  The mobile phase consisting of ethylacetate: methanol: 
water (10:1.35:1) with spray reagent 10% methanolic KOH 
gave the Rf value (0.41) same to that of the reference 
standard value of Psoralen. 
  The spot was detected by UV chamber method (Non-
Destructive method) at 365 nm. It was observed that the 
violet colour indicated the Psoralen Rf value. The TLC 
values are shown in the Figure 1 and  Table 2.
 
Figure 1. Thin layer chromatography of psoralen.
3.1.2. Drug-excipient compatability studies
  The FT-IR spectrum of Psoralen pure drug showed the 
characteristic peaks at 1 611.97, 1 566.90 due to C=C 
bond stretching and 1 706.72 due to C=O bond stretching 
of ketone group and 3 145.55, 3 057.61 due to C-H bond 
stretching that is due to CH2 functional group and 1 
382.73, 1 318.09 due to C-O bond stretching. 
  The IR spectrum of the Psoralen formulation clearly 
shows the retention of these peaks of Psoralen pure drug 
thus revealing no interaction between selected drug and 
polymers (Figure 2).
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Figure 2. Fourier transform infrared of psoralen (a) and 
formulation F3 (b).
3.1.3. SEM
  Surface topography, particle size, morphology of 
the gels were investigated with a scanning electron 
microscope. SEM is one of the common methods used 
owing to the simplicity of sample preparation and ease 
of operation. 
  Even 3D information about macro (0.1-10.0 mm), 
meso (1-100 μm) and microstructure (10-1 000 nm) is 
often found in the same micrograph. Scanning electron 
photomicrographs of placebo gel and formulation F3 
are shown in the Figure 3. Psoralen gel containing egg 
albumin and xanthan gum shows better incorporation of 
the drug.
(a)
(b)
Figure 3. Scanning electron microphotography of placebo gel (a) 
and formulation 3 (b). 
3.2. Evaluation of prepared psoralen gel
3.2.1. Physical examination
  F3 formulation consisting of egg albumin and 
xanthan gum was white in colour, viscous, smooth and 
homogenous in nature. This may be due to the nature of 
gelling agent that gives a clear appearance.
Table 2     
Thin layer chromatography for psoralen.
No. Sample Mobile phase Spray reagent Colour developed Rf value Results
1. 0.01 g psoralen+ CHCl3 CHCl3:Methanol (9:1) Anisaldehyde solution Violet 0.92 Failed
2. 0.01 g psoralen+ Methanol Toulene:Ethylacetaete (7.5:2.5) Anisaldehyde solution Violet 0.80 Failed
3. 0.01 g psoralen+ Methanol Toulene:Ethylacetate:Diethylamine (7:2:1) Dragandroff’s reagent Violet 0.61 Failed
4. 0.01 g psoralen+ Methanol Ethylacetate:Methanol:Water (10.00:1.35:1.00) 10% methanolic KOH Violet (at 365 nm) 0.41 Passed
Table 3    
pH, drug content, viscosity of the prepared formulations.
Formulation code pH Viscosity (cps ×103) Consistency Drug content (%)
F1 6.8   92 Gel consistency   96.1
F2 6.9   94 Gel consistency   99.0
F3 6.8   90 Gel consistency 106.0
F4 6.9 111 Gel consistency   98.5
F5 7.0 110 Gel consistency   95.5
F6 7.2 114 Gel consistency   96.0
F7 6.7   85 Transparent Gel   97.0
F8 6.7   87 Transparent Gel   99.6
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3.2.2. pH
  pH of all the prepared psoralen gel formulations 
ranged from 6.7-7.2 is considered acceptable to avoid 
the risk of irritation upon application to the skin.
3.2.3. Viscosity
  Gel formulation majorly depends upon its viscosity. 
Viscosity of the formulation affects the drug release 
from the gel. If a gel consists of more viscosity the 
drug release from the formulation is decreased and if 
the same gel possess less viscosity the drug diffuses 
immediately into the diffusion medium. Hence for the 
gel formulation optimum viscosity is necessary to get 
the maximum drug release. 
3.2.4. Spreadability and consistency
  All formulations showed good spreadability when 
applied between the horizontal plates. Consistency of 
these formulations was acceptable and smooth when 
applied. 
3.2.5. Homogeneity
  Formulations showed better homogeneity with the 
absence of clumps in these formulations.
3.2.6. Drug content
  Drug content was performed to estimate the amount 
of the Psoralen drug present in the prepared gel 
formulations. The pH values, viscosity, consistency, % 
drug content were given in the Table 3.
3.2.7. In-vitro diffusion study
  Diffusion studies were performed using Franz diffusion 
cell apparatus. Accurately weighed quantity of sample 
was placed over the donor compartment. Aliquots of 
samples were withdrawn at specific intervals and drug 
release was determined. At the end of 24 h the mean % 
drug release of each formulation was given in Figure 4. 
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Figure 4. Diffusion profiles for the formulation (F1-F9).
3.2.8. Release kinetics
  Data obtained from in vitro release studies of the 
Psoralen from various gel formulations were fitted to 
various kinetic equations such as Zero order, First 
order, Higuchi model and Korsmeyer-Peppas model and 
the results are presented in Table 4 and Figure 5. The 
release of Psoralen from the gel was First order diffusion 
as indicated by higher R2 values in First order kinetics 
and Higuchi model.
3.2.9. Stability studies
 Stability of a drug in a dosage form at different 
environmental conditions is important as it determines 
Table 4    
Release kinetics of formulation F1, F3, and F8.
Formulation code
Zero order First order Higuchi model Korsmeyer peppas model
R R2 R R2  R  R2  R  R2
F1  0.981 0.963 -0.991 0.982 0.972 0.945 0.943 0.890
F3 0.940 0.884 -0.988 0.976 0.975 0.951 0.976 0.951
F8  0.957 0.916 -0.993 0.987 0.981 0.963 0.980 0.960
Table 5 
Stability studies of F1, F3 and F8 at 0 °C, (27依2) °C, and (40依2) °C (75% RH).
Formulation code Physical appearance  pH Consistency % Drug content Result
F1 Change in colour due to interaction - - - Rejected
F3 No change No change No change No change Accepted
F8 No change No change Change observed - Rejected
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the expiry date of that particular formulation. Changes 
in the physical appearance, colour, odor, texture 
of the formulation indicate the drug stability. The 
results of stability studies are given in the table. The 
gels were separately subjected to a temperature of 0 
°C, room temperature of (27±2) °C and (40±2) °C for 1 
month. Periodically (initially 15 days, up to 30 days 
interval) samples were removed and characterized by 
pH, viscosity, in-vitro drug release study. Evaluation 
parameters of the formulations F1, F3 and F8 were given 
in Table 5 and physical changes along with stability 
studies are shown in Figures 6 and 7.
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Figure 5. First order (a) and Higuchi model (b) comparative 
release kinetics of the formulations F1, F3, and F8.
  Formulation F3 when subjected to freezer (0 °C) 
showed a considerable change in drug content and also 
decreases in release profile. Storage at (40±2) °C also 
showed change in colour, consistency, pH, viscosity, 
drug content, and release profile. This may be due to 
the fact that egg albumin is natural in origin and it gets 
denatured at high temperatures.
Formulation F2
Formulation F3Formulation F8(a) (b)
Formulation F1
Figure 6. Physical appearance of the formulation F1, F2, F3 and 
F8 after 3 weeks. 
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Figure 7. Stability studies of the formulations F3 (a) and F8 at 
different temperatures (75% RH). 
  Hence it is clear that the gel containing egg albumin 
and xanthan gum (F3 formulation) is stable at room 
temperature and stability study data are shown in Table 
6 and Figure 7a.
3.2.10. In-vitro anti-psoriatic activity
  The mouse-tail model is based on the induction of 
orthokeratosis in those parts of the adult mouse-tail, 
which have a normally parakeratotic differentiation. 
Saline and Formulation 3 (egg albumin and xanthan 
gum) were applied topically in the form of a gel. In 
the mouse tail test, Psoralen produced significant 
Table 6  
Stability studies of formulation F3.
Evaluation parameter Initial 
0 °C Room temperature
15 d of observation 30 d of observation 15 d of observation 30 d of observation
Physical appearance Clear white in colour  No change No change No change No change
pH   6.87   6.85   6.80   6.86   6.87
% Drug content 81.80 78.00 77.06 80.00 80.30
% Drug diffused 45.32 44.60 44.00 43.10 43.90
Table 7 
Effect of psoralen on the degree of orthokeratosis and drug activity in mouse-tail (mean±SEM) (n=6).
Group Orthokeratosis (%) Drug activity (%)
Control group (Saline solution) 17.00±2.30 -
Treated group (Formulation F3) 53.00±0.98 43.3
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orthokeratosis when compared to control. Parakeratotic 
condition is seen in the adult mouse tail which is one of 
the hallmarks of psoriasis. 
  The presence of nucleus in the control was more in 
number. The Formulation 3 (egg albumin and xanthan 
gum) containing Psoralen drug showed decrease in 
the number of nucleus which shows the increase in 
orthokeratotic activity. Saline that acts as control 
showed 20% orthokeratosis whereas the Formulation 
3 showed 53% orthokeratosis in mouse tail. The drug 
activity was found to be 43.3%. Anti-psoriatic drug 
enhances the orthokeratotic cell differentiation in the 
epidermal scales. Orthokeratosis and drug activity in 
the mouse tail are shown in Table 7 and Figure 8.
Orthokeratosis
(b)
(a)
Figure 8. Cross-section through the skin of the mouse tail 
treated topically with saline solution (Control group, Figure 8a) or 
with formulation F3 (Treated group, Figure 8b).
4. Discussion
  Topical formulations are advantageous over oral 
formulations as they avoid gastrointestinal drug 
absorption difficulties caused by gastrointestinal pH 
and enzymatic activity. Formulations containing egg 
albumin and xanthan gum showed more release rates 
when compared to formulations containing egg albumin 
and Guar gum. Release of drug from the gels was first 
order diffusion controlled as indicated by higher r2 
values in first order kinetic and Higuchi model and the 
n values obtained from the Korsmeyer–Peppas model 
showed that the release mechanism was non-fickian.
  F3 formulation showed 82% drug release in 24 h. On 
application to the skin the gel leaves the cooling effect, 
no gritty particles on the surface of the skin and also no 
irritation to the skin. In vitro anti-psoriatic activity of 
F3 showed the significant orthokeratosis in the mouse 
tail test when compared to control thus indicating that 
the formulation is effective in treating psoriasis.
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